Apyx Medical (NASDAQ:APYX) Rating Increased to Buy at BTIG Research

BTIG Research upgraded shares of Apyx Medical (NASDAQ:APYX) from a neutral rating to a buy rating in a research note released on Wednesday morning, MarketBeat reports. They currently have $6.00 target price on the stock.

A number of other research firms also recently commented on APYX. Citizens Jmp upgraded Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research report on Wednesday, November 12th. Zacks Research raised shares of Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. Roth Mkm initiated coverage on shares of Apyx Medical in a research note on Monday, December 15th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.50.

Apyx Medical Stock Performance

NASDAQ:APYX opened at $3.93 on Wednesday. The company has a debt-to-equity ratio of 5.69, a current ratio of 4.44 and a quick ratio of 3.61. The firm has a market capitalization of $150.29 million, a price-to-earnings ratio of -14.56 and a beta of 1.61. The company’s 50-day moving average is $3.75 and its two-hundred day moving average is $3.31. Apyx Medical has a 1-year low of $0.76 and a 1-year high of $4.50.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $19.12 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 139.09%. Analysts forecast that Apyx Medical will post -0.68 EPS for the current year.

Institutional Investors Weigh In On Apyx Medical

Several institutional investors have recently modified their holdings of APYX. AIGH Capital Management LLC acquired a new position in shares of Apyx Medical in the 4th quarter valued at $3,867,000. Nantahala Capital Management LLC increased its position in Apyx Medical by 19.1% during the fourth quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock worth $13,909,000 after buying an additional 636,043 shares during the period. Informed Momentum Co LLC acquired a new stake in shares of Apyx Medical in the fourth quarter valued at approximately $863,000. Huntleigh Advisors Inc. purchased a new position in shares of Apyx Medical during the fourth quarter worth approximately $827,000. Finally, 683 Capital Management LLC acquired a new position in shares of Apyx Medical in the 4th quarter valued at $436,000. 55.33% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Craig Hallum raised its price target to $6.00 and initiated/maintained a “buy” view, implying ~52.7% upside from recent levels — a catalyst for bullish investor sentiment. Article Title Article Title
• Positive Sentiment: BTIG upgraded APYX from Neutral to Buy and set a $6.00 target, reinforcing the positive analyst momentum. Article Title Article Title
• Positive Sentiment: Q4 results slightly beat expectations: EPS of ($0.03) vs. consensus ($0.06) and revenue of $19.16M vs. $19.12M — the beat and management commentary (record revenue / strategic growth) support the upgrade momentum. Article Title Press Release
• Positive Sentiment: Management raised FY2026 revenue guidance to $57.5M–$58.5M vs. street ~$55.9M and outlined a 9%–11% revenue growth target as AYON rollout accelerates — suggests better topline visibility into 2026. Press Release Article Title
• Neutral Sentiment: Analyst coverage and press summaries (earnings breakdowns and call highlights) are amplifying the story for investors but mostly restate the beats/guidance. Article Title
• Negative Sentiment: Short interest has shown increases earlier in the period (Feb short interest ~173,573 shares, +22.3%), and the company still posts negative margins and ROE — these remain downside risks if execution lags. (March short-interest data appears inconsistent/zero in some reports and may reflect a reporting anomaly.)

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.